journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Neurological Disorders

journal
https://www.readbyqxmd.com/read/27800024/an-update-on-the-evidence-base-for-peginterferon-%C3%AE-1a-in-the-treatment-of-relapsing-remitting-multiple-sclerosis
#1
REVIEW
Pavan Bhargava, Scott D Newsome
Peginterferon β1a is a modified form of interferon β1a with a polyethylene glycol (PEG) group attached to the α-amino group of the N terminus of the interferon molecule. This modification alters the pharmacokinetic and pharmacodynamic properties of interferon β1a, enabling reduced frequency of dosing and may also result in reduced immunogenicity of the interferon β1a molecule. The efficacy of peginterferon β1a 125 µg administered subcutaneously every 2 or 4 weeks was demonstrated at the end of the placebo-controlled period in the phase III ADVANCE study; both dosing regimens met their primary endpoint of reducing annualized relapse rate (ARR) compared with placebo...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27800023/brivaracetam-as-adjunctive-therapy-for-the-treatment-of-partial-onset-seizures-in-patients-with-epilepsy-the-current-evidence-base
#2
REVIEW
Christian Brandt, Theodor W May, Christian G Bien
Brivaracetam (BRV) is a novel antiepileptic drug recently licensed for the treatment of partial epilepsy in adults and adolescents over 16 years old. Like levetiracetam (LEV), it is a ligand of the synaptic vesicle protein SV2A. BRV has been shown in animal models and in studies using human brain slices to have a higher SV2A affinity and faster penetration into the brain. Its efficacy and safety have been shown in several randomized, controlled studies. The recommended initial dose is 50-100 mg, divided into two daily doses...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27800022/evidence-for-the-use-of-pimavanserin-in-the-treatment-of-parkinson-s-disease-psychosis
#3
REVIEW
Harini Sarva, Claire Henchcliffe
Parkinson's disease (PD) is a progressive neurodegenerative disorder with both motor and nonmotor symptoms (NMS), leading to significant morbidity and caregiver burden. Psychosis is common but is under recognized by physicians. When present, it increases the patient's risk of hospitalization and nursing home placement and caregiver burden. Although the atypical antipsychotic agent, clozapine, has been considered the gold standard treatment, severe agranulocytosis in 0.38% of patients and more commonly milder leukopenia, resulting in frequent blood testing, limit its use...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27800021/efficacy-and-tolerability-of-dimethyl-fumarate-in-white-african-and-hispanic-americans-with-multiple-sclerosis
#4
Lana Zhovtis Ryerson, Rivka Green, Gladyne Confident, Krupa Pandey, Benjamin Richter, Tamar Bacon, Carrie Sammarco, Lisa Laing, Jennifer Kalina, Ilya Kister
BACKGROUND: Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (RRMS) based on two phase III randomized clinical trials (RCTs). There were not enough non-White patients enrolled in these RCTs to allow for subgroup analysis based on race. Efficacy and tolerability of DMF therapy across various racial groups is unknown. METHODS: Retrospective chart review was performed on all patients with RRMS who were started on DMF in two tertiary multiple sclerosis (MS) clinics...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27800020/two-year-real-world-experience-with-perampanel-in-patients-with-refractory-focal-epilepsy-austrian-data
#5
Alexandra Rohracher, Gudrun Kalss, Markus Leitinger, Claudia Granbichler, Ildiko Deak, Judith Dobesberger, Giorgi Kuchukhidze, Aljoscha Thomschewski, Julia Höfler, Eugen Trinka
BACKGROUND: The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD: A retrospective 2-year chart review of all patients receiving perampanel was carried out. RESULTS: A total of 122 patients received perampanel [median treatment length: 20...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582898/usefulness-of-optical-coherence-tomography-to-distinguish-optic-neuritis-associated-with-aqp4-or-mog-in-neuromyelitis-optica-spectrum-disorders
#6
Elena H Martinez-Lapiscina, Maria Sepulveda, Ruben Torres-Torres, Salut Alba-Arbalat, Sara Llufriu, Yolanda Blanco, Ana M Guerrero-Zamora, Nuria Sola-Valls, Santiago Ortiz-Perez, Pablo Villoslada, Bernardo Sanchez-Dalmau, Albert Saiz
No abstract text is available yet for this article.
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582897/poststroke-epilepsy-update-and-future-directions
#7
REVIEW
Johan Zelano
Stroke is among the most common causes of epilepsy after middle age. Patients with poststroke epilepsy (PSE) differ in several respects from patients with other forms of structural-metabolic epilepsy; not least in age, age-related sensitivity to side effects of antiepileptic drugs (AEDs), and specific drug-drug interaction issues related to secondary-stroke prophylaxis. Encouragingly, there has lately been remarkable activity in the study of PSE. Three developments in PSE research deserve particular focus. First, large prospective trials have established the incidence and risk factors of PSE in the setting of modern stroke care...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582896/eletriptan-in-the-management-of-acute-migraine-an-update-on-the-evidence-for-efficacy-safety-and-consistent-response
#8
REVIEW
Matilde Capi, Martina Curto, Luana Lionetto, Fernando de Andrés, Giovanna Gentile, Andrea Negro, Paolo Martelletti
Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks. In this paper, we review the recent data on eletriptan clinical efficacy, safety, and tolerability, and potential clinically relevant interactions with other drugs. Among triptans, eletriptan shows a consistent and significant clinical efficacy and a good tolerability profile in the treatment of migraine, especially for patients with cardiovascular risk factors without coronary artery disease...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582895/the-physiological-basis-of-therapies-for-cerebellar-ataxias
#9
REVIEW
Hiroshi Mitoma, Mario Manto
Cerebellar ataxias represent a group of heterogeneous disorders impacting on activities of daily living and quality of life. Various therapies have been proposed to improve symptoms in cerebellar ataxias. This review examines the physiological background of the various treatments currently administered worldwide. We analyze the mechanisms of action of drugs with a focus on aminopyridines and other antiataxic medications, of noninvasive cerebellar stimulation, and of motor rehabilitation. Considering the cerebellum as a controller, we propose the novel concept of 'restorable stage'...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582894/children-with-multiple-sclerosis-should-not-become-therapeutic-hostages
#10
REVIEW
Klaus Rose, Thomas Müller
BACKGROUND: Both the United States (US) Food and Drug Administration (FDA) and the European Union (EU) European Medicines Agency (EMA) order pediatric clinical trials as a condition for approval of new compounds. We evaluate clinical value and likelihood of sufficient recruitment for pediatric multiple sclerosis (pMS) studies and discuss US and EU pediatric legislation with pMS as a paradigm. METHODS: We analyzed pMS clinical trials requested by the FDA and the EMA and industry-sponsored pMS studies registered on www...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582893/combination-treatment-of-fingolimod-with-antidepressants-in-relapsing-remitting-multiple-sclerosis-patients-with-depression-a-multicentre-open-label-study-regain
#11
Antonios Bayas, Katrin Schuh, Monika Baier, Stefan Viktor Vormfelde
OBJECTIVES: Approximately one in two patients with multiple sclerosis (MS) suffer from comorbid depression. The primary objective of this study was to evaluate the safety and tolerability of fingolimod and antidepressant combination in relapsing-remitting MS patients with mild-to-moderate depression. Efficacy outcome variables were quality of life (QoL), fatigue, disability and depression. METHODS: Patients received open-label fingolimod 0.5 mg over 2 weeks, followed by fingolimod plus citalopram (40 mg), fluoxetine (40 mg) or venlafaxine (150 mg) over 16 weeks...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582892/evaluation-of-positive-and-negative-predictors-of-seizure-outcomes-among-patients-with-immune-mediated-epilepsy-a-meta-analysis
#12
Divyanshu Dubey, Zehra Farzal, Ryan Hays, L Steven Brown, Steven Vernino
BACKGROUND: The objective of this study was to analyze published literature on autoimmune epilepsy and assess predictors of seizure outcome. METHODS: From PubMed and EMBASE databases, two reviewers independently identified publications reporting clinical presentations, management and outcomes of patients with autoimmune epilepsy. A meta-analysis of 46 selected studies was performed. Demographic/clinical variables (sex, age, clinical presentation, epilepsy focus, magnetic resonance imaging [MRI] characteristics, time to diagnosis and initiation of immunomodulatory therapy, and type of immunomodulatory therapy) were compared between two outcome groups (responders and nonresponders)...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582891/novel-oral-anticoagulants-for-the-secondary-prevention-of-cerebral-ischemia-a-network-meta-analysis
#13
Aristeidis H Katsanos, Dimitris Mavridis, John Parissis, Spyridon Deftereos, Alexandra Frogoudaki, Agathi-Rosa Vrettou, Ignatios Ikonomidis, Maria Chondrogianni, Apostolos Safouris, Angeliki Filippatou, Konstantinos Voumvourakis, Nikos Triantafyllou, John Ellul, Theodore Karapanayiotides, Sotirios Giannopoulos, Anne W Alexandrov, Andrei V Alexandrov, Georgios Tsivgoulis
BACKGROUND: Novel oral anticoagulants (NOACs) have shown to be both safe and effective for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). We conducted a network meta-analysis (NMA) using published data from secondary prevention subgroups of different phase III randomized clinical trials (RCTs) comparing individual NOACs with warfarin. METHODS: Eligible studies were identified by searching MEDLINE and SCOPUS and the Cochrane Central Register of Controlled Trials databases...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27582890/percutaneous-transluminal-angioplasty-and-stenting-for-symptomatic-intracranial-arterial-stenosis-a-systematic-review-and-meta-analysis
#14
Georgios Tsivgoulis, Aristeidis H Katsanos, Georgios Magoufis, Odysseas Kargiotis, Georgios Papadimitropoulos, Konstantinos Vadikolias, Theodoros Karapanayiotides, John Ellul, Anne W Alexandrov, Panayiotis D Mitsias, Andrei V Alexandrov
OBJECTIVES: The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS: We conducted a systematic review and random effects meta-analysis of all available randomized controlled trials (RCTs) evaluating the safety and efficacy of PTAS (in comparison with medical therapy) for sICAS...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27366242/dimethyl-fumarate-may-still-have-a-role-in-progressive-multiple-sclerosis
#15
Domenico Plantone, Floriana De Angelis, Anisha Doshi, Jeremy Chataway
No abstract text is available yet for this article.
July 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27366241/subcutaneous-immunoglobulins-in-the-treatment-of-chronic-immune-mediated-neuropathies
#16
REVIEW
Verena I Leussink, Hans-Peter Hartung, Bernd C Kieseier, Mark Stettner
Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes, subcutaneous immunoglobulins (SCIgs) have represented a mainstay for decades. An emerging body of evidence suggests that SCIg might also exhibit clinical efficacy in CIDP and MMN. This article reviews the current evidence for clinical effectiveness, as well as safety of SCIg for the treatment of immune-mediated neuropathies, and addresses remaining open questions in this context...
July 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27366240/web-based-interventions-in-multiple-sclerosis-the-potential-of-tele-rehabilitation
#17
REVIEW
Alexander Tallner, Klaus Pfeifer, Mathias Mäurer
The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function in persons with MS (pwMS). In this review we give an overview on several online exercise programs for pwMS and discuss the advantages and drawbacks of web-based interventions. Although participants of online exercise programs reported a high acceptance and satisfaction with the intervention, decreasing compliance was a major issue...
July 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27366239/the-diagnosis-and-management-of-idiopathic-intracranial-hypertension-and-the-associated-headache
#18
REVIEW
Rigmor Højland Jensen, Aleksandra Radojicic, Hanne Yri
Idiopathic intracranial hypertension (IIH) is a challenging disorder with a rapid increasing incidence due to a close relation to obesity. The onset of symptoms is often insidious and patients may see many different specialists before the IIH diagnosis is settled. A summary of diagnosis, symptoms, headache characteristics and course, as well as existing evidence of treatment strategies is presented and strategies for investigations and management are proposed.
July 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27366238/clinical-efficacy-of-combined-sodium-dimercaptopropanesulfonate-and-zinc-treatment-in-neurological-wilson-s-disease-with-d-penicillamine-treatment-failure
#19
Dingbang Chen, Xiangxue Zhou, Haiman Hou, Li Feng, JunXiu Liu, Yinyin Liang, Xiaopu Lin, Jiwei Zhang, Chao Wu, Xiuling Liang, Zhong Pei, Xunhua Li
OBJECTIVES: There are limited pharmacological treatments for patients with neurological Wilson's disease (WD) and a history of copper-chelating treatment failure. METHODS: We retrospectively evaluated the clinical records of 38 patients with WD who were treated with sodium dimercaptopropanesulfonate (DMPS) and zinc (group 1) or zinc alone (group 2). All patients had a history of neurological deterioration during their previous treatment with D-penicillamine (DPA)...
July 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27366237/direct-stroke-unit-admission-of-intravenous-tissue-plasminogen-activator-safety-clinical-outcome-and-hospital-cost-savings
#20
Anne W Alexandrov, Kisha C Coleman, Paola Palazzo, Reza Bavarsad Shahripour, Andrei V Alexandrov
BACKGROUND: In the USA, stable intravenous tissue plasminogen activator (IV tPA) patients have traditionally been cared for in an intensive care unit (ICU). We examined the safety of using an acuity-adaptable stroke unit (SU) to manage IV tPA patients. METHODS: We conducted an observational study of consecutive patients admitted to our acuity-adaptable SU over the first 3 years of operation. Safety was assessed by symptomatic intracerebral hemorrhage (sICH) rates, systemic hemorrhage (SH) rates, tPA-related deaths, and transfers from SU to ICU; cost savings and length of stay (LOS) were determined...
July 2016: Therapeutic Advances in Neurological Disorders
journal
journal
42104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"